BioCentury
ARTICLE | Company News

Shire, HydroMed amend Histrelin deal

December 27, 2001 8:00 AM UTC

Hydro Med (Cranbury, N.J.) and Shire (LSE:SHP; SHPGY) amended a licensing deal for HydroMed's Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. As amended, Hydro Med will be respon...